Scholarlink

<p>Despite advances in early detection and treatment, the prognosis for advanced gastric cancer (GC) remains poor, highlighting the need to explore molecular mechanisms driving tumor progression. Phosphorylated Signal Transducer and Activator of Transcription 3 (p-STAT3) is a central mediator in these processes, but its role in GC biology and prognostic significance remains controversial. We analyzed p-STAT3 expression in tumor and adjacent normal tissues from 68 GC patients using immunohistochemistry and evaluated associations with inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), tumor characteristics, and survival outcomes. p-STAT3 positivity was significantly higher in GC tissues (32.4%) than in normal tissues (13.2%, <i>p</i> = 0.008). Positive p-STAT3 expression correlated with elevated NLR (<i>p</i> = 0.014) and PLR (<i>p</i> = 0.041). Although tumor stage, size, and lymph node metastasis did not show significant differences in p-STAT3 expression (<i>p</i> &gt; 0.05), multivariate analysis identified p-STAT3 as an independent predictor of poor survival (HR = 5.711, 95% CI 1.180–27.643; <i>p</i><b> = </b>0.030). p-STAT3-positive patients had significantly worse cumulative survival rates (47.4%) compared to p-STAT3-negative patients (92.7%, <i>p</i> = 0.001). These results indicate that p-STAT3 overexpression is linked to systemic inflammation and poor prognosis, highlighting its potential as a therapeutic target in GC management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

p-STAT3 expression associates with prognosis and inflammatory indexes in gastric cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Doanh Hieu Tran,
  • Thanh Son Le,
  • Trong Hoe Nguyen,
  • Khac Thao Thai,
  • Thi Mai Ly Nguyen,
  • Thi Phuong Linh Nham,
  • Ngoc Dung Tran,
  • Thuy Linh Nguyen,
  • Linh Toan Nguyen,
  • Khac Cuong Bui

摘要

Despite advances in early detection and treatment, the prognosis for advanced gastric cancer (GC) remains poor, highlighting the need to explore molecular mechanisms driving tumor progression. Phosphorylated Signal Transducer and Activator of Transcription 3 (p-STAT3) is a central mediator in these processes, but its role in GC biology and prognostic significance remains controversial. We analyzed p-STAT3 expression in tumor and adjacent normal tissues from 68 GC patients using immunohistochemistry and evaluated associations with inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), tumor characteristics, and survival outcomes. p-STAT3 positivity was significantly higher in GC tissues (32.4%) than in normal tissues (13.2%, p = 0.008). Positive p-STAT3 expression correlated with elevated NLR (p = 0.014) and PLR (p = 0.041). Although tumor stage, size, and lymph node metastasis did not show significant differences in p-STAT3 expression (p > 0.05), multivariate analysis identified p-STAT3 as an independent predictor of poor survival (HR = 5.711, 95% CI 1.180–27.643; p = 0.030). p-STAT3-positive patients had significantly worse cumulative survival rates (47.4%) compared to p-STAT3-negative patients (92.7%, p = 0.001). These results indicate that p-STAT3 overexpression is linked to systemic inflammation and poor prognosis, highlighting its potential as a therapeutic target in GC management.